Johnson & Johnson’s acquisition strategy has largely focused on medical technology companies in the past few years, as the healthcare giant splashes another $13.1 billion
→ Just a few weeks after Amgen touted its efforts in rare disease, EVP of R&D in that therapeutic area is departing to lead R&D at
The Federal Trade Commission will have more time to review Novo Holdings’ proposed $16.5 billion acquisition of Catalent. The application was originally filed to the
Just like other cell therapy companies, Caribou Biosciences is entering the autoimmune disease field. The Berkeley, CA-based biotech disclosed Thursday afternoon that the FDA cleared
The CDC wants clinicians and health departments to consider potential infections with the highly pathogenic avian influenza (HPAI) A(H5N1) virus, commonly known as bird flu,
Rep. Greg Murphy, MD (R-N.C.), will speak at the American College of Emergency Physicians’ (ACEP) leadership meeting later this month, despite calls for the congressman
Use of hypoglossal nerve stimulation (HGNS) may be effective for treating obstructive sleep apnea (OSA), but a higher body mass index (BMI) and supine sleeping
Driven by increased life expectancy and related changes in age structure, global prostate cancer cases will more than double over the next 15 years, a
The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid cancers. The action represents
Brain iron accumulated in people with acute post-traumatic headache, an imaging study showed. Higher levels of iron based on T2* signal changes were seen in